We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold Nanoparticles Improve Cellular Signaling in Novel Heart Repair Tissue

By LabMedica International staff writers
Posted on 09 Oct 2014
An Israeli research team has developed a novel gold nanoparticle-based approach for repairing damaged heart tissue.

Human heart cells cultured on ECM (extracellular matrix) scaffoldings of animal origin (usually pig) form a tissue that generates its own electrical impulses and expands and contracts spontaneously. More...
However, residual proteins and antigens from animal sources can trigger pathogenic immune responses following implantation of these tissues.

Investigators at Tel Aviv University (Israel) avoided the immune response problem by constructing scaffolding from a patient's own stomach wall tissue. In a further refinement, they integrated gold nanoparticles into this hybrid cardiac tissue in order to optimize electrical signaling between the cells.

Results published in the September 1, 2014, online edition of the journal Nano Letters revealed that cardiac cells engineered within these hybrid scaffolds exhibited elongated and aligned morphology, massive striation, and organized connexin 43 electrical coupling proteins. Furthermore, the hybrid patches demonstrated superior function as compared to pristine patches, including a stronger contraction force, lower excitation threshold, and faster calcium transients.

"Our goal was twofold," said senior author Dr. Tal Dvir, professor of molecular microbiology and biotechnology at Tel Aviv University, "to engineer tissue that would not trigger an immune response in the patient and to fabricate a functional patch not beset by signaling or conductivity problems. To address our electrical signaling problem, we deposited gold nanoparticles on the surface of our patient-harvested matrix, "decorating" the biomaterial with conductors. The result was that the nonimmunogenic hybrid patch contracted nicely due to the nanoparticles, transferring electrical signals much faster and more efficiently than non-modified scaffolds. We now have to prove that these autologous hybrid cardiac patches improve heart function after heart attacks with minimal immune response. Then we plan to move it to large animals and after that, to clinical trials."

Related Links:
Tel Aviv University



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.